TRITON-TIMI 38
Trial to Assess Improvement in Therapeutic Outcomes
Doente / População Intervenção / Exposição Comparação Desfecho
In 13,608 ACS patients undergoing planned PCI, prasugrel reduced ischaemic events but increased major bleeding relative to clopidogrel.
N
13 608
Desenho
Double-blind RCT
Desfecho
CV death, non-fatal MI or non-fatal stroke
Relevância
2
Resultado9.9 % vs 12.1 % (HR 0.81). TIMI major bleed 2.4 % vs 1.8 %; fatal bleed higher with prasugrel.
Wiviott SD, et al. N Engl J Med. 2007;357(20):2001-2015. 10.1056/NEJMoa0706482
Discussão e crítica
Net harm in patients > 75 y, < 60 kg, or with prior stroke/TIA — these subgroups are contraindications. Selection of P2Y12 inhibitor remains a balance of ischaemic vs bleeding risk.